Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04650321 · ClinicalTrials.gov registry record · Phase 4
Home Based Infusions for Ocrelizumab
A Phase 4 study of Multiple Sclerosis, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 110
- Enrollment target
- 1
- Study location
NCT04650321: Recruiting Phase 4 study of Multiple Sclerosis, sponsored by University of Colorado, Denver.
NCT04650321 is a Phase 4 study of Multiple Sclerosis that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 110 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04650321, a Phase 4 study of Multiple Sclerosis, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 110 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal is to assess the safety and effectiveness of home ocrelizumab infusion.
Primary Outcome
Proportion of patients with infusion reactions greater than or equal to 3 on the National Cancer Institute's Common Terminology
Conditions Studied
Interventions
- DRUG Ocrelizumab at home
Study Locations (1)
Colorado
- Amerita - Centennial
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2021-03-01 |
| Est. Completion | 2021-08-31 |
| Phase | Phase 4 |
What NCT04650321 shows while recruiting
NCT04650321 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Ocrelizumab at home is the first listed.
NCT04650321 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT04650321 about?
NCT04650321 is a clinical study titled "Home Based Infusions for Ocrelizumab". The goal is to assess the safety and effectiveness of home ocrelizumab infusion.
What is the current status of trial NCT04650321?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 110 participants. The study started on 2021-03-01. Estimated completion is 2021-08-31.
What conditions does trial NCT04650321 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT04650321?
The interventions under investigation include: Ocrelizumab at home (DRUG).
Who is sponsoring clinical trial NCT04650321?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04650321 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04650321's enrollment target sits among peer trials
110 124th of 315 higher than 191 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis
RECRUITING · Phase 4
-
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
RECRUITING · Phase 4
-
Glucose Consumption in MS Using [F-18]FDG-PET
RECRUITING · Phase 4
-
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
RECRUITING · Phase 4
-
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
RECRUITING · Phase 4
-
Cladribine Tablets After Treatment With Natalizumab (CLADRINA)
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI